Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward looking statements for purposes of the safe harbor provisions of the Private S

A First In Man Phase 1 Study Of CUDC 907, a First In Class Chemically Designed Dual Inhibitor Of PI3K and HDAC In Patients With Refractory Or Relapsed Lymphoma and Multiple Myeloma. American Society of Hematology Annual Meeting and Exposition, 7 10 December 2013, Abstract No. 4363 11 CUDC 907 Summary Inhibitor of PI3K alpha, delta, beta and key HDAC enzymes Exclusive worldwide rights Potent activity in lymphoma and multiple myeloma models Phase 1 dose escalation completion projected mid 2014 Clinical PK as predicted from animal model studies Improved tolerability with intermittent schedule (2x or 3x weekly) Expected to permit higher doses than daily schedule Preliminary evidence of clinical activity in 11 patients 1 PR, 7 SD Expansion cohorts in 2H 2014 (DLBCL, MM) Phase 2 testing projected for late 2014 Clinical testing in solid tumor indication(s) anticipated in late 2014 12 CUDC 427: Antagonist of IAP (Inhibitor of Apoptosis) Proteins 13 CUDC 427: Antagonist of IAP Proteins In licensed from Genentech, Nov. 2012 Exclusive, worldwide license No call back or reach through provisions Oral small molecule, monovalent SMAC mimetic drug candidate Targets and inhibits IAP proteins cIAP1, cIAP2, XIAP, ML IAP Synergy with chemotherapy or TNF demonstrated Genentech completed Phase 1 dose escalation clinical trial 42 patients with solid tumors or lymphoma Well tolerated using 14 days on and 7 days off administration schedule Significant biomarker activity starting at ~ 90mg dose Complete responses (n=2) Disease stabilization 3 months observed (n=4) Liver enzyme increases and rash observed at higher doses ( 450mg dose) 14 CUDC 427 and Apoptosis Induction TNF Caspase 8 Caspase 9 Caspase 3, 7 Bid Bax/Bak Cytochrome C Smac Extrinsic Intrinsic NF kB Mitochondria Apoptosis Non canonical Pathway Canonical Pathway CUDC CUDC 427 CUDC CUDC 427 Oral small molecule drug Monovalent SMAC mimetic Synergy with apoptosis inducing agents: chemotherapy or TNF cIAPs cIAPs ML IAP XIAP 15 CUDC 427 Phase 1 Trial Summary Phase 1 monotherapy trial executed by Genentech Design Dose escalation study in patients with refractory solid tumors or lymphoma 42 patients in 11 cohorts 5mg to 600mg once daily dosing, 14 days on and 7 days off schedule Results Dose proportional PK with no evidence of drug accumulation MTD not determined Rapid down modulation of cIAP target in circulating PBMC and tumor biopsies 2 patients with complete responses (CR) 8 patients with stable disease (SD, 4 of which lasted 3 months) 16 CUDC 427 Phase 1 Trial Clinical Activity Two patients had complete response MALT lymphoma (300 mg): CR by PET let in Cycle 5 (off study patient choice) Ovarian cancer (450 mg): CR end of Cycle 2 (off study due to AE, rash) Sustained CR per imaging Feb 2013 July 31, 2012 April 18, 2012 17 CUDC 427 Clinical Development Status Curis initiated Phase 1 study using monotherapy continuous bi daily administration schedule July 2013 1 patient death due to liver failure October 2013 FDA partial clinical hold November 2013 Response to FDA in final preparation; submission shortly Further development contingent on FDA lift of partial clinical hold Capecitabine combination Phase 1b/2 trial in HER 2 negative breast cancer Monotherapy in patients with genetic alterations in IAP pathway components Potential indications: MALT lymphoma Trial start dependent on development of genetic screening assay Other combination treatment trials pending results of preclinical studies Chemotherapy Targeted therapies 18 CUDC 427 Summary Potent antagonist of IAP proteins Exclusive worldwide rights Orally available small molecule drug Preclinical efficacy and synergy with chemotherapy or TNF Phase 1 monotherapy studies Discontinuous daily regimen well tolerated (formal MTD not reached) Clinical benefit observed in patient with IAP pathway genetic alteration MALT lymphoma with cIAP2 gene amplification: 300mg / 5 cycles CR Continuous bi daily treatment not well tolerated Combination therapy CUDC 427 + capecitabine Phase 1b/2 trial planned contingent on FDA lifting partial clinical hold Additional combination trials projected based on preclinical data TNF inducers, apoptosis inducing agents, biologics 19 Erivedge : First in class Hedgehog Pathway Inhibitor 20 Erivedge Developed Under Collaboration Genentech and Roche Erivedge (vismodegib) Oral inhibitor of Hedgehog signaling pathway Discovered under broad pathway collaboration formed in 2003 Approved for treatment of advanced basal cell carcinoma (BCC) Genentech/Roche sponsored trial completed in less severe, operable BCC Genentech/Roche sponsored trial initiated in AML and MDS Several investigator sponsored studies are ongoing in other cancers Milestone and royalty based revenue stream for Curis Potential for $115 million in development regulatory milestones $56 million received to date Royalties on global net sales 21 Marketed in the U.S. for the treatment of advanced BCC Roche recorded ~ $51 million net sales first 9 months 2013 32% growth 3Q ($21.4 million) vs. 2Q ($16.2 million) Anticipated continued sales growth in 2014 Near term Erivedge royalties primarily fund non recourse loan from Pharmakon, subject to quarterly caps (estimated full repayment early 2017) Expand global marketing Roche Approved in U.S., Australia, European Union and multiple other countries Reimbursement discussions ongoing in Ex US territories Filed with health authorities in many other countries Genentech plans to present operable BCC Phase 2 trial results in 1Q 2014 Erivedge Launched in Multiple Countries Genentech and Roche 22 Initiated Phase 1b/2 study of Erivedge in patients with AML and high risk MDS in October 2013 Study design Approx. 60 patients across 2 cohorts Primary endpoint: ORR after 8 weeks of treatment Secondary endpoints: ORR rate at any time during treatment, duration of response, OS and safety and PK Roche Continues to Invest in Erivedge Cohort 1: 150 mg Erivedge daily Cohort 2: 150 mg Erivedge daily + cytarabine for 10 days 23 Debio 0932: Second Generation, Oral HSP90 Inhibitor Phase 1/2 DebioPharm 24 Second generation oral small molecule Hsp90 inhibitor Exclusive worldwide license with Debiopharm $90 million in potential payments ($13 million received to date) Royalties on net sales; share of certain sublicensing payments Clinical development status Debiopharm Completed Phase 1 Study 50 subjects Of 8 NSCLC patients: 1 PR (mut KRAS), 4 SD Phase 1 portion of Phase 1/2 HALO study in Stage IIIb/IV NSCLC patients In combination with chemotherapy, front line and previously treated patients Debiopharm anticipates Phase 2 initiation in mid 2014 (milestone payment) Initiated Phase 1 study in renal cell carcinoma in 2013 In combination with everolimus Debiopharm anticipates Phase 2 initiation in 2H 2014 (milestone payment) Debio 0932 Oral Small Molecule Hsp90 Inhibitor 25 CUDC 101: EGFR/Her2 and HDAC inhibitor Strong preclinical evidence of synergistic inhibition of multiple signaling pathways Phase 1 and Phase 1b studies completed using intravenous administration 71 patients as monotherapy activity in liver cancer patients 12 patients in combination with chemoradiation activity in SCCHN patients Intravenous administration not feasible to maintain recommended exposure levels Phase 1 study conducted using oral administration captisol formulation 3 patients treated study halted due to low drug exposure Efforts to develop an new oral formulation of CUDC 101 with adequate bioavailability have been unsuccessful Curis will not invest further in CUDC 101 without securing a partnership Discovery research Ongoing efforts focused on backup compounds and third generation EGFR inhibitor chemical scaffolds CUDC 101 and EGFR Discovery Program 26 September 30, 2013 (000 s) Cash, cash equivalents, investments (1) $ 67,100 Erivedge secured debt (non recourse to Curis) $ 30,600 Basic shares outstanding 84,100 Fully diluted shares outstanding (2) 96,000 Net loss through September 30, 2013 $ (8,100) (1) Curis received an additional $6.8 million in net proceeds through the sale of 1.56 million shares under its at the market sales agreement, which settled in early October.

The forward looking statements included in this presentation represent our views as of the date of this presentation. We anticipate that subsequent events and developments will cause our views to change. While we may elect to update these forward looking statements in the future, we specifically disclaim any obligation to do so. These forward looking statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation. 2 HDAC/PI3K Indications Indications Market Market NSCLC Lymphomas and Multiple Myeloma Target Target Program Program Preclinical Preclinical Phase 1 Phase 1 Phase 2 Phase 2 Phase 3 Phase 3 CUDC 907 Debio 0932 Clinical Pipeline Novel, Targeted Cancer Therapeutics Renal Cancer Advanced Basal Cell Carcinoma Operable Basal Cell Carcinoma Erivedge AML and MDS Proprietary Programs Partnered Programs Hsp90 Hedgehog IAP CUDC 427 Breast, Ovarian, Lymphomas, and Other Cancers Phase 1* Phase 1 Approved in US, AUS, EU Others Phase 2 Phase 1b/2 Phase 1 Phase 1/2 * CUDC 427 is currently on an FDA partial clinical hold. 3 CUDC 907: Potent Inhibitor of HDAC and PI3K Enzymes 4 Oral, first in class highly potent and selective inhibitor of HDAC and PI3K enzymes Preclinical highlights Hematological indications clinical highlights Clinical testing in solid tumor indication(s) anticipated in late 2014 CUDC 907 Summary Inhibition of PI3K, MAPK and JAK/STAT pathways in hematologic tumor models Potential biomarkers predicting CUDC 907 sensitivity Phase 1 dose escalation study ongoing in lymphoma and multiple myeloma patients Side effect profile consistent with target inhibition thrombocytopenia, diarrhea, fatigue Preliminary evidence of anti tumor activity based on 1 PR 7 SD out of 13 patients Dose escalation phase projected for completion in mid 2014 Dose expansion phase (DLBCL MM) projected for initiation in 2H 2014 Phase 2 testing in hematological indication(s) anticipated late 2014 5 CUDC 907: Dual Activity against HDAC PI3K M2 ~ 80% PI3K activity as compared to parent No HDAC activity M1 ~ 30% PI3K activity as compared to parent No HDAC activity PI3K IC50 (nM) Alpha Delta Beta Gamma 19 39 54 311 HDAC IC50 (nM) 1 2 3 6 10 4, 5, 7, 8, 9 1.7 5.0 1.8 27 2.8 200 CUDC 907 Full HDAC activity Full PI3K activity H 2 N O R R R H O O R HDACi Moiety PI3Ki Moiety 6 CUDC 907 M2 Tissue Distribution in Mouse Informs Clinical PK Model Mouse 25 mg/kg Single Dose, PO Differential kinetics distribution of CUDC 907 M2 metabolite M1 M2 levels higher in plasma than CUDC 907 levels CUDC 907 is predominantly distributed to tissues CUDC 907 M2 7 CUDC 907: Phase 1 Clinical Design Phase 1 dose escalation monotherapy study Relapsed/refractory lymphoma or multiple myeloma patients MSKCC (Anas Younes, MD), SCRI (Jesus Berdeja, MD), MDACC (Yasuhiro Oki, MD) 3+3 design 1 o Objective Determination of MTD and recommended Phase 2 dose (RP2D) 2 o Objectives Safety tolerability Pharmacokinetics and biomarkers of CUDC 907 activity Anti cancer activity 21 day cycles testing 3 different administration schedules (oral dosing) Daily: MTD reached BIW (Mon/Thu): dose escalation ongoing TIW (Mon/Wed/Fri): dose escalation ongoing 8 CUDC 907: Phase 1 Clinical PK Plasma levels of CUDC 907 Metabolites Apparent increase in exposure with higher doses Differential kinetics of CUDC 907 metabolites Higher M1 M2 levels compared to CUDC 907 in plasma samples Model: metabolites are generated from tissue distributed CUDC 907 Potential accumulation of metabolites with daily dosing supports intermittent dosing Anticipate higher CUDC 907 exposure in tissue vs. plasma Day 1 D8 Day 15 Day 1 Day 15 D8 Day 1 Day 15 17 D8 9 CUDC 907: Phase 1 Clinical Safety Daily dosing schedule Intermittent dosing schedules (BIW, TIW) Common side effects consistent with target modulation thrombocytopenia, diarrhea and fatigue MTD at 30mg dose level Treatment related AEs dosing interruptions for thrombocytopenia and/or neutropenia 2 DLTs (G3 diarrhea G4 hyperglycemia) in 1 subject at 60mg dose level No treatment related adverse events observed thus far 60 mg cohort 10 11 subjects were evaluable for response (i.e., 1 post treatment response assessments) 1 subject with mixed FL/DLBCL achieved PR (70% reduction in target lesion) in Cycle 4 (30mg daily dose level) 7 subjects achieved SD 4 subjects with 4 cycles of study treatment (to date) 1 subject is currently in Cycle 15 of study treatment (MM) *Note: Concurrent PD documented as new lesions CUDC 907: Phase 1 Best Tumor Response Observed to Date (Study Ongoing) Younes A, Flinn IW, Oki Y, et al.

0 NASDAQ: CRIS Corporate Overview January 13, 2014 Exhibit 99.1 1 Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results or events could differ materially from the expectations, plans and prospects disclosed in the forward looking statements that the Company makes due to a number of important factors, including risks related to: the Company s ability to satisfactorily respond to the FDA s request for additional data and analysis regarding CUDC 427 with respect to the partial clinical hold and its ability to conduct future preclinical or clinical studies involving CUDC 427 if the FDA or other regulatory agencies continue to express safety concerns even if the hold is lifted; Genentech and Roche s ability to successfully develop and commercialize Erivedge; the Company s and its collaborators ability to successfully research, obtain regulatory approvals for, develop and commercialize products based upon the Company s technologies; the Erivedge royalty collateralized loan transaction entered into by the Company s wholly owned subsidiary, including the risk that it may not receive sufficient levels of royalty revenue from sales of Erivedge to satisfy the debt obligation or may otherwise lose its rights to royalties and royalty related payments as a result of a foreclosure of the loan; the Company s ability to obtain and maintain proprietary protection for its technologies and product candidates; competitive pressures; the Company s ability to raise additional funds to finance its operations; and those risk factors discussed in the Company s Quarterly Report on Form 10 Q for the quarter ended September 30, 2013, and other reports that it files with SEC.

(2) Comprised of: (i) 84.1 million shares outstanding, (ii) warrants to purchase 1.4 million shares at $3.55 per share, and (iii) options to purchase 10.5 million shares at a weighted average exercise price of $2.86 per share. Summary Financial Data 27 NASDAQ: CRIS